Equities Analysts Offer Predictions for Avantor Q1 Earnings

Avantor, Inc. (NYSE:AVTR) – William Blair lowered their Q1 2025 earnings estimates for shares of Avantor in a note issued to investors on Monday, February 10th. William Blair analyst M. Larew now anticipates that the company will post earnings per share of $0.22 for the quarter, down from their previous estimate of $0.24. The consensus estimate for Avantor’s current full-year earnings is $0.98 per share. William Blair also issued estimates for Avantor’s Q2 2025 earnings at $0.26 EPS, Q4 2025 earnings at $0.30 EPS, FY2025 earnings at $1.07 EPS, Q1 2026 earnings at $0.27 EPS, Q2 2026 earnings at $0.30 EPS, Q3 2026 earnings at $0.31 EPS, Q4 2026 earnings at $0.35 EPS and FY2026 earnings at $1.23 EPS.

Several other analysts have also weighed in on the company. Royal Bank of Canada reduced their price objective on Avantor from $33.00 to $31.00 and set an “outperform” rating on the stock in a research note on Monday. Morgan Stanley reduced their price target on shares of Avantor from $27.00 to $25.00 and set an “overweight” rating on the stock in a research note on Monday. Robert W. Baird lowered their price objective on shares of Avantor from $27.00 to $26.00 and set an “outperform” rating for the company in a research report on Monday, October 28th. Stifel Nicolaus cut their target price on shares of Avantor from $28.00 to $26.00 and set a “buy” rating on the stock in a research report on Monday. Finally, UBS Group reiterated a “neutral” rating and set a $25.00 price target (down from $29.00) on shares of Avantor in a report on Friday, January 17th. Three equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat.com, Avantor has an average rating of “Moderate Buy” and a consensus target price of $26.15.

Avantor Price Performance

Shares of NYSE AVTR opened at $18.42 on Wednesday. The stock has a market capitalization of $12.53 billion, a PE ratio of 40.03, a P/E/G ratio of 3.87 and a beta of 1.28. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.54 and a quick ratio of 1.06. Avantor has a fifty-two week low of $18.19 and a fifty-two week high of $28.00. The business has a fifty day moving average price of $21.68 and a two-hundred day moving average price of $23.44.

Avantor (NYSE:AVTR) last announced its quarterly earnings results on Wednesday, February 12th. The company reported $0.27 EPS for the quarter, beating analysts’ consensus estimates of $0.26 by $0.01. Avantor had a net margin of 4.54% and a return on equity of 12.24%. During the same period last year, the company posted $0.22 EPS.

Institutional Investors Weigh In On Avantor

Several large investors have recently modified their holdings of the stock. MassMutual Private Wealth & Trust FSB raised its position in shares of Avantor by 99.5% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,253 shares of the company’s stock valued at $26,000 after purchasing an additional 625 shares during the period. Smartleaf Asset Management LLC raised its holdings in Avantor by 106.3% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,611 shares of the company’s stock valued at $34,000 after acquiring an additional 830 shares during the period. UMB Bank n.a. bought a new stake in Avantor during the 3rd quarter valued at $49,000. Nisa Investment Advisors LLC lifted its position in shares of Avantor by 69.6% during the third quarter. Nisa Investment Advisors LLC now owns 2,035 shares of the company’s stock worth $53,000 after acquiring an additional 835 shares in the last quarter. Finally, Global Retirement Partners LLC boosted its holdings in shares of Avantor by 76.7% in the fourth quarter. Global Retirement Partners LLC now owns 2,459 shares of the company’s stock worth $52,000 after acquiring an additional 1,067 shares during the period. Hedge funds and other institutional investors own 95.08% of the company’s stock.

About Avantor

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.